<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Unrelated donor (URD) bone marrow transplantation (BMT) in adults can be associated with high non-relapse mortality (NRM) </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, factors determining survival in 136 human leucocyte antigen (HLA)-A, B, DRB1-matched adult BMT recipients were reviewed </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-four per cent of patients had <z:hpo ids='HP_0011010'>chronic</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>) and 36% had <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GvHD) prophylaxis was either <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CSA)/<z:chebi fb="0" ids="44185">methotrexate</z:chebi> (64%) or T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> and CSA/<z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (34%) </plain></SENT>
<SENT sid="4" pm="."><plain>The probability of donor engraftment by d 45 was 97% (95% CI: 94-100) </plain></SENT>
<SENT sid="5" pm="."><plain>Incidence of grades III-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GvHD was 18% (95% CI: 12-24) at 100 d, and <z:hpo ids='HP_0011010'>chronic</z:hpo> GvHD was 42% (95% CI: 32-52) at 2 years </plain></SENT>
<SENT sid="6" pm="."><plain>At 2 years, 14% (95% CI: 8-20) had relapsed </plain></SENT>
<SENT sid="7" pm="."><plain>Multiple regression analysis showed that adverse risk factors for survival were non-<z:mp ids='MP_0005481'>CML</z:mp> diagnosis, age &gt; 35 years, diagnosis to transplant time of &gt; 18 months [<z:hpo ids='HP_0011010'>chronic</z:hpo>-phase <z:mp ids='MP_0005481'>CML</z:mp> (<z:mp ids='MP_0005481'>CML</z:mp>-CP) only]; and grades III-IV <z:hpo ids='HP_0011009'>acute</z:hpo> GvHD </plain></SENT>
<SENT sid="8" pm="."><plain>Patients &lt;or= 35 years with early <z:mp ids='MP_0005481'>CML</z:mp>-CP had a 2 year survival of 77% (95% CI: 54-100), which compared with a survival in advanced <z:mp ids='MP_0005481'>CML</z:mp> patients &lt;or=35 years of 67% (95% CI: 37-97) and 37% (95% CI: 20-54) in non-<z:mp ids='MP_0005481'>CML</z:mp> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Two year survival for patients &gt; 35 years with early <z:mp ids='MP_0005481'>CML</z:mp>-CP was 55% (95% CI: 33-77), 40% (95% CI: 19-61) in advanced <z:mp ids='MP_0005481'>CML</z:mp> and 14% (95% CI:1-27) in non-<z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Future efforts should focus on improving the outcome for older BMT recipients, especially those with diagnoses other than <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
</text></document>